Northeast Pharmaceutical Group Co Ltd (000597) - Total Liabilities
Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has total liabilities worth CN¥8.05 Billion CNY (≈ $1.18 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000597 operating cash flow to assess how effectively this company generates cash.
Northeast Pharmaceutical Group Co Ltd - Total Liabilities Trend (1993–2024)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 000597 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Northeast Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
China | CN¥145.26 Million |
|
DLG Exhibitions & Events Corp Ltd
SHG:600826
|
China | CN¥1.57 Billion |
|
Shinyoung Securities Co. Ltd.
KO:001720
|
Korea | ₩10.12 Trillion |
|
Ultra Jaya Milk Industry Tbk
JK:ULTJ
|
Indonesia | Rp937.01 Billion |
|
Cansino Biologics Inc
SHG:688185
|
China | CN¥2.37 Billion |
|
Liquidity Services Inc
NASDAQ:LQDT
|
USA | $153.88 Million |
|
Coursera Inc
NYSE:COUR
|
USA | $364.30 Million |
|
Otokar Otomotiv ve Savunma Sanayi AS
IS:OTKAR
|
Turkey | TL57.04 Billion |
Liability Composition Analysis (1993–2024)
This chart breaks down Northeast Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Northeast Pharmaceutical Group Co Ltd (000597) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Northeast Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Northeast Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual total liabilities of Northeast Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥8.88 Billion ≈ $1.30 Billion |
-12.24% |
| 2023-12-31 | CN¥10.11 Billion ≈ $1.48 Billion |
+11.19% |
| 2022-12-31 | CN¥9.10 Billion ≈ $1.33 Billion |
+2.34% |
| 2021-12-31 | CN¥8.89 Billion ≈ $1.30 Billion |
+10.51% |
| 2020-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
-6.71% |
| 2019-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
+6.11% |
| 2018-12-31 | CN¥8.13 Billion ≈ $1.19 Billion |
+1.01% |
| 2017-12-31 | CN¥8.05 Billion ≈ $1.18 Billion |
+9.37% |
| 2016-12-31 | CN¥7.36 Billion ≈ $1.08 Billion |
+16.92% |
| 2015-12-31 | CN¥6.29 Billion ≈ $920.66 Million |
+8.26% |
| 2014-12-31 | CN¥5.81 Billion ≈ $850.43 Million |
-2.42% |
| 2013-12-31 | CN¥5.96 Billion ≈ $871.48 Million |
+40.36% |
| 2012-12-31 | CN¥4.24 Billion ≈ $620.88 Million |
+2.74% |
| 2011-12-31 | CN¥4.13 Billion ≈ $604.29 Million |
+16.65% |
| 2010-12-31 | CN¥3.54 Billion ≈ $518.05 Million |
-12.05% |
| 2009-12-31 | CN¥4.03 Billion ≈ $589.03 Million |
+59.14% |
| 2008-12-31 | CN¥2.53 Billion ≈ $370.14 Million |
+16.99% |
| 2007-12-31 | CN¥2.16 Billion ≈ $316.38 Million |
+68.91% |
| 2006-12-31 | CN¥1.28 Billion ≈ $187.31 Million |
-8.43% |
| 2005-12-31 | CN¥1.40 Billion ≈ $204.54 Million |
-9.84% |
| 2004-12-31 | CN¥1.55 Billion ≈ $226.86 Million |
-6.13% |
| 2003-12-31 | CN¥1.65 Billion ≈ $241.66 Million |
-8.64% |
| 2002-12-31 | CN¥1.81 Billion ≈ $264.52 Million |
-3.47% |
| 2001-12-31 | CN¥1.87 Billion ≈ $274.02 Million |
+6.18% |
| 2000-12-31 | CN¥1.76 Billion ≈ $258.08 Million |
+1.85% |
| 1999-12-31 | CN¥1.73 Billion ≈ $253.39 Million |
+8.84% |
| 1998-12-31 | CN¥1.59 Billion ≈ $232.81 Million |
+29.30% |
| 1997-12-31 | CN¥1.23 Billion ≈ $180.06 Million |
-41.48% |
| 1996-12-31 | CN¥2.10 Billion ≈ $307.68 Million |
+25.37% |
| 1995-12-31 | CN¥1.68 Billion ≈ $245.42 Million |
+50.97% |
| 1994-12-31 | CN¥1.11 Billion ≈ $162.56 Million |
+5.56% |
| 1993-12-31 | CN¥1.05 Billion ≈ $154.01 Million |
-- |
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti-infection products, such as fosfomycin series, azithromycin series, amantadine series, berberine hydroch… Read more